

Evolution of Medicine and Agriculture in the 20th century

Medicine

- Increasingly specialized
- Technology driven

Price of medical care increased

Agriculture

- Increasingly specialized
- Technology driven
- Dependent on antibiotics
 Dependent on antibiotics
 - Price of food decreased

Uses of Antibiotics Livestock Humans - Growth - Prevention Prevention - Treatment - Treatment All uses lead to antibiotic resistance

Defining Terms

- Low dose
- Sub-therapeutic
- Non-therapeutic
- Growth promoting All mean essentially the same thing.
- Typically mean levels as low as 1-2 parts per million in feed.
- Higher doses, up to 100 parts per million or higher used to treat sick animals.

Resistant Salmonella typhimurium and Enterococcus faecium drove policy

Zoonotic Bacteria


- Cause illness in both livestock and people. Major cause of food-borne illness.
- Salmonella enterica (subspecies: Salmonella typhimurium)
- Campylobacter species.

<u>Gram negative</u>: Stain pink S. Typhimurium Campylobacter E. coli


Indicator Bacteria

- Part of normal intestinal microbiome in both animals and people. Can cause lifethreatening illnesses.
- Escherichia coli (E. coli)
- Enterococcus (Enterococcus faecium and Enterococcus faecalis)

Gram positive: Stain blue Enterococcus





Accidental Discovery of Antibiotics as Growth Promoting Agents in 1940's Work at Lederle Labs, Division of American Cyanamid Company Fed vitamin B12 to chicks and piglets Growth rates increased Residues from chlortetracycline Increased efficiency in agriculture. Adopted in many countries




FDA never "approved" antibiotics for growth promotion in livestock
The Penicillin Amendment of 1945
Allowed FDA to waive the requirements to ensure the safety and efficacy of penicillin-based drugs if doing so was considered safe.

- Waiver provided FDA the flexibility to approve antibiotics for purposes other than treating infections.
- In 1951 and 1953, respectively, FDA waived requirements for batch certification of antibiotics intended as growth promoting agents and preventive agents in livestock.







Teleclass broadcast sponsored by Virox Technologies Inc. www.virox.com) A Webber Training Teleclass www.webbertraining.com











www.webbertraining.com







Teleclass broadcast sponsored by Virox Technologies Inc. www.virox.com) A Webber Training Teleclass www.webbertraining.com


Sweden

- Swedes highly concerned about the environment after Rachel Carson's book *Silent Spring* published in 1962.
- In 1977, in response to Swann Report, banned some antibiotics for growth promotion that were also used in clinical medicine.
- In 1981, series of newspaper articles in *Dagens Nyheter* (Daily News)reported that more than 30 tons of antibiotics used in animal feed for growth promotion each year. Public was outraged.











The Rise of Vancomycin-Resistant Enterococcus faecium (VRE)


- In 1988, first case reports of VRE reported in seriously ill patients in Paris (acute leukemia) and London (End Stage Kidney Failure).
- Three months before the London VRE cases, a new policy was implemented: administer vancomycin and ceftazidime to all chronically ill (i.e. end stage kidney failure) patients with fever and undiagnosed infections.
- A few years later, VRE was isolated from food animals in England and Germany.
- Avoparcin, a growth promoting agent in livestock, chemically related to vancomycin and used in Europe since the early 1970's, was implicated as the probable source of VRE in hospitals.


Growth Promoting Antibiotic in Livestock	Related Antibiotic in Human Medicine	Antibiotic Class
Avoparcin	Vancomycin	Glycopeptide
Antibiotic	Enterococcus faecium	Enterococcus faecalis
Ampicillin/Gentamicin of Ampicillin/Cephtriaxone	+ increasing resistance	+
Vancomycin	+	+
	ram positive bacteria. proved by FDA Sept. 1999, o April 2000, only treats <i>E. faec</i>	· · · ·




















Teleclass broadcast sponsored by Virox Technologies Inc. www.virox.com) A Webber Training Teleclass www.webbertraining.com













Teleclass broadcast sponsored by Virox Technologies Inc. www.virox.com) A Webber Training Teleclass www.webbertraining.com









Teleclass broadcast sponsored by Virox Technologies Inc. www.virox.com) A Webber Training Teleclass www.webbertraining.com


United States


- US never approved avoparcin because of concerns about its carcinogenicity, so epidemiology of VRE has been different compared to Europe.
- Congress has spent decades debating the risks of growth promoting antibiotics.
- Consistently concluded that more data was needed, but never appropriated resources to get more data.
- Bureaucratic leaders at CDC, FDA, USDA scrounged together funds for NARMS and NAHMS.

VRE in U.S.


- VRE in US emerged in 1990's in hospitals.
- Preceded spread in European hospitals by about a decade even though first few cases reported in Europe.
- CDC estimates that 77% of US healthcare-associated infections due to *Enterococcus faecium* are resistant to vancomycin.*
- CDC estimates approximately 10,000 VRE infections and 650 deaths per year.*
- Healthcare costs specifically for VRE not available.
- CDC estimates that >2 million people fall ill with resistant infections, 23,000 die, healthcare costs between \$20 to \$35 billion per year.*

*CDC. Antibiotic Resistance Threats in the United States 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf





Teleclass broadcast sponsored by Virox Technologies Inc. www.virox.com) A Webber Training Teleclass www.webbertraining.com




National Antibiotic Resistance Monitoring System (NARMS): Enterococcus faecium


Antibiotic	Chickens* 2003 2006 %∆ (2216) (1500)			Chicl 2002 (134		1 %∆	Pork Chops 2002 2011 %Δ (93) (37)		
Vancomycin	0	0	0	0	0	0	0	0	0
Linezolid	0	0	0	0	0	0	0	0	0
Quinupristin/ dalfopristin	36.9	65.8	+28.9	55. 4^	32.1^	-23.3	24.7^	13.5^	-11.2
	es not co	ollect En	terococcu	ıs faec	<i>ium</i> data	on huma	ans!		
NARMS do									
NARMS do eccified Enterococcu erococcus faecium A NARMS: //www.ars.usda.go	resistance								


National Animal Health Monitoring System (NAHMS): Resistant Enterococcus in Pigs

Antibiotic	2006 (857)*	%	2012 (563)*	%	Change
Vancomycin	0	0	0	0	0
Linezolid	0	0	0	0	0
g Susceptibility. April 20	terococcus on U.S. Swine 09.			faecium (7.9%).	
DA APHIS Commensal En g Susceptibility. April 20 erococcus species includ mundtii (7.7%), E. casseli	terococcus on U.S. Swine 09. Ied: E. hirae (29.6%), E. fi flavus (3%) and others.	aecalis (27.4%), E. specie	ntimicrobial is not identified (16%), E. 2006/Swine2006 is entr		


Antibiotic Ceftriaxone	Chickens 1997 2011 %Δ (214) (491)		Chicken Meat 2002 2011 %Δ (60) (158)		Swine 1997 2011 %∆ (111) (90)		Pork Chops 2002 2011 %∆ (10) (28)		Humans 2002 2011 %Δ (1998) (2344)						
	0.5	6.3	+5.8	10	33.5	+23. 5	0	2.2	+2.2	20	7.1	-12. 9	4.4	2.5	-1.9
Ciprofloxacin	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.2	+0.1
Tetracyclines	20.6	40.9	+20. 3	33.3	65.8	+32. 5	52.3	41.1	-11.2	70	39.3	-30.7	14.9	10.5	-4.4
Frimethoprim/ Sulfamethoxazol	0.5	0.2	-0.3	0	1.3	+1. 3	1.8	0	-1.8	20	0	-20	1.4	1.2	-0.2









*Acar J, Casewell M, Freeman J, et al. Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making. Clinical Microbiology and Infection. Sept. 2000 6(9): 477-482.







<image><image><image><image><image><image>

Two Danish studies

1. First Danish study analyzed fecal specimens from 127 healthy dogs and found 20 *E. faecium* isolates resistant to ampicillin. One isolate was related to VRE CC17. Only 14 dogs had been treated with antibiotics within 6 months of the study.

2. Second Danish/UK study found ampicillin resistant *E. faecium* in 61/208 dogs. Only 1 person out of 18 tested positive—a 10 year old boy. 1 in every 4 dogs tested had AREF CC17, precursor to VRE CC17.

 Damborg P, Sorensen AH, Guardabassi L. Monitoring of antimicrobial resistance in healthy dogs: first report of canine ampicillin-resistant Enterococcus faecium clonal complex 17. 2008; 132: 190-196.
 Damborg P, Top J, Hendrick AP et al. Dogs are a reservoir of ampicilline-resistant Enterococcus faecium lineages associated with human infections. Applied and Environmental Microbiology 2009; 75: 2360-2365.

